DARTMOUTH, Mass., Jan. 17 -- The University of Massachusetts at Dartmouth issued the following news release:
UMass Dartmouth'sAdvanced Technology & Manufacturing Center (ATMC) welcomes Boston 3T Biotechnologies as a new addition to its Center this month. ATMC provides infrastructure for emerging companies, such as Boston 3T Biotechnologies, as they grow and develop into the future technology and manufacturing leaders regionally, nationally, and internationally.
"Our drug discovery development covers various disciplines including virology, cell biology, and immunology, protein engineering, and cancer vaccines," said President and CEO of Boston 3T Biotechnologies, Dr. Meijia Yang. "Boston 3T Biotechnologies is dutifully committed to the development of cell-base therapies for patients and becoming a demonstrated leader in the therapeutic discovery and manufacture sciences."
Boston 3T Biotechnologies is a start-up company founded by a group of scientists from both the pharmaceutical industry and academic institutions. The company is a pre-clinical stage startup that has invented innovative cancer treatment technology through the use of genetically modified cytokine-induced, killer cells (CIK). The proprietary technology serves as a T cell receptor gene during the therapeutic process and is integrated into the cancer patient's own cells. The engineered gene redirects the killer cells to the tumor tissues, thereby attacking the cancer cells. In addition, the CIK cells also reverse the suppression of immune cells.
Last month, ATMC welcomed O'Neill Power Systems (O'Neill), which develops innovative lightweight unmanned aerial vehicle ("UAV") helicopter power systems that increase safety, performance, fuel efficiency and reliability.
Twelve companies in clean energy, marine technology, biotechnology and life sciences, and the software industry are currently occupying space at ATMC. ATMC has fifteen successful graduate companies, 80% of which stayed in Massachusetts to help grow the local economy. The center experienced combined annual sales of over $50 million in 2013 and historically its companies have generated over 200 jobs.
"We are excited to add Boston 3T Biotechnologies to the ATMC portfolio," said Paul Vigeant, Director of ATMC. "We look forward to Boston 3T Biotechnologies building upon its cutting edge, innovative treatment technology and making its own mark in its development of therapies to patients."
The Advanced Technology and Manufacturing Center (ATMC) of the University of Massachusetts Dartmouth provides advanced technology and manufacturing solutions, through industry and university partnerships, to meet current and future business needs. ATMC is located in the South Coast Research and Technology Park, near the intersection of Routes 195 and 24 in Fall River, within a 60,000 sq. ft. state-of-the-art technology facility. For more information, please visit www.atmc.umassd.edu.
TNS 30TagarumaMar-140118-4607219 30TagarumaMar